Rhinomed Limited

Rhinomed is an ASX listed (RNO:AU) Melbourne Australia based medical technology firm that has developed a patented nasal and respiratory technology platform capable of radically improving the way you breathe, sleep, maintain your health and take medication. The Company is focused on solving clear, unmet needs in the global sport and exercise, sleep, wellness and drug delivery markets. Rhinomed's management team and board consists of experienced professionals from the biotech, medical, consumer health and global consumer goods industries. Our strategy is to build a significant customer base consisting of consumers, patients and clinicians, who use the platform technology across a range of applications. Mute is a compelling solution to major unmet needs in the global sleep aid market which was valued at $54.9b in 2013. By increasing the volume of air traveling through the nose during sleep, alleviating congestion and encouraging nasal breathing, Mute has been shown to not only reduce snoring but also radically improve sleep quality in users and their partners. www.mutesnoring.com Turbine is a sports breathing technology designed to make breathing easier during aerobic activity. Designed to sit comfortably inside the nose, Turbine allows athletes to take in an average of 38% more air with every breath. By optimizing every breath and making it easier and more efficient to do so, Turbine may improve performance, boost endurance and aid recovery. Turbine has been readily adopted by some of the world's leading elite athletes including 2013 & 2015 Tour de France winner, Chris Froome. www.theturbine.com

• Employees 19
• Founded 2013
• Annual Revenue $4978000
• Total Funding $5852470